Akers Biosciences Share Discussion Threads

[algernon2] 09/1/2015 21:11

Azzi,yes the devices are very utilitarian and clunky looking but I am sure I read/heard that AKR had an Italian designer redesigning the products to make them presumably more aesthetic(sorely needed).

Hopefully if they get slimmed down and more rounded and less "Clunky" then they will store/stack/ship more easily and attract the eye more.

Heres hoping.
The "Jury is out" I believe like most of you here.Could go either way.

[werewolfie] 09/1/2015 20:56

I'm giving them another year - i still don't think things have really kicked off yet. I wasn't anticipating a profit so i'm not disappointed. But im not keeping my money in here forever, thats 2 years now and the share price has barely moved. Although the potential has increased greatly, and thats the only reason Im sticking around

I get the strong impression Dr Walt should stay in the lab and not wear a business hat - Good enough for Steve Jobs, good enough for him

[azzi] 09/1/2015 20:50

Hi folks,
Well I have said this before, and I'll say it again....I'm still here!, fully invested for the past few years....for entertainment...of course!
I'm not here to knock the management. I could...but....!!! Enough has already said/implied.
Frankly this could go either way and won't make a jot of difference to me in reality, however, I remain fascinated to understand the philosophy of the company. There have been some very positive recent announcements which on the face of it should be applauded, However since investing I have tried to accumulate a view of the REAL quality of AKR's core products. I won't bore you with a full breakdown of my views, unfortunately I became a non-believer. The exception was the PIFA technology. Now I need re-assurance that the technology is REALLY as good as it is claimed. From what I understand the technology is based on devices that are 20 year old clunky devices - please can someone put me straight on this?
Bonne nuit!
Azzi

[mcmather] 09/1/2015 19:40

vancoille, you decide.

23 July 2013 - Dr Raymond Akers disposes of 7m shares; roughly £140,000.
8 August 2013 - Proposed Nasdaq listing.
18 November 2013 - Share consolidation; 156/1.
23 January 2014 - Listing opens on Nasdaq.
14 May 2014 - Q1 2014 results - Net loss $595,600 mainly due to costs associated with NASDAQ IPO.
12 August 2014 - Q2 2014 results - Net loss $494,995 Three factors contributed to the increased loss: maintaining dual listings of our stock has significantly increased costs associated with compliance with regulatory requirements, the expansion of sales and marketing efforts and stock option based compensation for our directors, officers and key employees.
13 November 2014 - Q3 2014 results - Net loss $1,124,320 as a result of hiring additional personnel, capital market commitments and marketing activities.
9 January 2015 - For services rendered and to be rendered to the Company the following receive:
Thomas J. Knox 50,000 shares = $187,500 (based on a share price of $3.75)
Brandon Knox 25,000 shares = $93,750 (based on a share price of $3.75)
Raymond F. Akers Jr 70,000 shares = $262,500 (based on a share price of $3.75)
Gavin Moran 35,000 shares = 131,250 (based on a share price of $3.75)

[vancoillie] 09/1/2015 17:50

The issue of equity,Is This a good or bad sign

[algernon2] 09/1/2015 16:53

Akers Biosciences, Inc. Issue of Equity

Aha!

[norbus] 09/1/2015 08:44

The generosity of AKRman is touching; gifted himself all the 70000 into a trust with no comeback as no one can touch; to Knox and knox he bequeathed a bundle more

[norbus] 06/1/2015 12:47

It's where you expect them to be this time next year that matters; If you do not believe in Alice , or little Red Riding Hood, you will make money arbitraging physical stock, so less risk on blips.

[mcmather] 06/1/2015 11:23

Reading between the lines suspect that we will see another $1m loss for Q4 2014.

Edwin C Hendrick's performance needs to be closely monitored. His remit is to expand / increase sales pertaining to the PIFA PF4 / Pluss device in the N America region.

Historically, this product / region has yielded annual sales of around $1m. Despite the initial bull and bonhomie of Dr Walt, Hendrick's performance to date - including in Q3 2014 - has been no better than what has gone on here since around 2007! This despite the fact that he is the only person who has also had the benefit of trying to sell the much lauded PIFA Pluss device.

That all said, from a technical perspective, the stock on nasdaq appears to be approaching a 'golden cross'; ie perhaps the current 'rally' might continue for a little while yet??

[rivaldo] 06/1/2015 08:44

Good to see the share price moving up nicely - there doesn't seem to be much stock around given that a single buy caused a tick up, whilst a sell achieved a good premium to the bid price.

Thanks for the summary above mcm, I'll have a listen myself later.

If AKR achieve those numbers this year then the share price should move a long way forward from here, especially considering the $10.2m cash pile against the £12.8m m/cap.

[mcmather] 05/1/2015 17:13

5 Jan 2015

"ORLANDO, Fla., Jan. 5, 2015 (GLOBE NEWSWIRE) -- RedChip Companies, Inc. today announced that "The RedChip Money Report: Small Stocks Big Money"(TM) television program host Dave Gentry interviewed Raymond F. Akers, Jr. PhD, Co-founder and Executive Chairman of Akers Biosciences (AKER). During the interview, Dr. Akers provides insight into the Company's current value, growth prospects, and overall opportunity.

The interview is now available online at:

Aegis Capital has an $11 per share price target on Akers Biosciences, which currently trades at 1.26x book value at $3.70 per share. During the interview, Dr. Akers reconfirms the Company's 2014 revenue guidance of $4 million to $5 million and forecasts 2015 revenues of $7.2 million to $10 million. Akers Biosciences is expected to reach profitability once it reaches $8.8 million in annual sales."

[mcmather] 05/1/2015 11:38

"Any" still being the operative / genuine word though.

10k buy / sell(?) at 255p. Rollover?

[norbus] 05/1/2015 08:18

I am genuinely pleased for any success story;

[rivaldo] 05/1/2015 07:41

Cheers re the news of both the new analyst report above and the US breath test approval.

An $11.80 share price would be around 760p - very nice indeed :o))

[mcmather] 04/1/2015 19:08

3 Jan 2015 - do not think this means too much other than it is approved for such pruposes / by the Department of Health:

Approved Prearrest and Evidential Breath Testing Devices

CONFORMING PRODUCTS LIST OF ALCOHOL SCREENING DEVICES

Akers Biosciences, Inc., Thorofare, New Jersey Breath Alcohol xx .02 Detection System.8
8 The Breath Alcohol xx .02 Detection System consists of a single-use disposable breath tube used in conjunction with an electronic analyzer that determines the test result. The electronic analyzer and the disposable breath tubes are lot specific and manufactured to remain calibrated throughout the shelf-life of the device. This screening device cannot be used after the expiration date.


"Prearrest breath testing devices approved under this authority may be used by police officers, waterways patrolmen and officers enforcing the Vehicle Code, the Fish and Boat Code and the Game and Wildlife Code in conducting preliminary determinations of the alcohol content of blood of persons suspected of driving, boating, hunting or furtaking while under the influence of alcohol. Officers and patrolmen use these devices to assist them in determining whether or not a person should be placed under arrest for violation of 75 Pa.C.S. § 3802 (relating to driving under influence of alcohol or controlled substance), for violation of 30 Pa.C.S. § 5502 (relating to operating watercraft under influence of alcohol or controlled substance), for violation of 34 Pa.C.S. § 2501 (relating to hunting or furtaking prohibited while under influence of alcohol or controlled substance) or for any other criminal offense under the Vehicle Code, the Fish and Boat Code or the Game and Wildlife Code which involves operating a vehicle or boat, hunting or furtaking while under the influence of alcohol."

[werewolfie] 02/1/2015 21:10

Target price for AKER is estimated at $11.80. The target price is based on the current P/S
multiple of 5.57x (ttm) and an estimated revenue of 10.5M or $2.12 per share. The target price is
well above today’s trading price of $4.15 leading to a buy recommendation for Aker. Today’s
price is considered an attractive entry point considering that AKER is trading just above the book
value (1.26x), has no debt, has significant cash in their balance sheet and is generating revenue
from its current product lines and has several new product lines launching in FY2015.
Summary & Conclusion
Aker Bioscience Inc. has much to smile about in the upcoming fiscal year. The PIFA Heparin PF4
Rapid Assay product line has been very successful in the US and has now been approved for
distribution in Europe (press release Dec 18). With several more product lines nearing distribution
stages, the outlook for FY 2015 is nothing but positive. Revenue is expected to double estimates
of FY2014 and share price is estimated at $11.80.

[werewolfie] 02/1/2015 21:08

Just read it Mcm - worth mentioning that the company has no debt either

Making this relatively small profit of $1m would gain a good bit of attention Im sure

[mcmather] 02/1/2015 17:02

The report from BrokerBank Securities suggests that revenue for Q4 2014 will be $1,936,279 with total revenue for 2014 being $5m and a net loss of $2.5m.

Revenue for 2015 projected at $10.5m with a profit of $1m......

[mcmather] 02/1/2015 14:50

2 Jan 2015 - Bright Outlook and New Products on the Way Prompt Analyst Report of Akers Bioscience Issued by BrokerBank Securities.

[mcmather] 02/1/2015 14:46

There does appear to be the opportunity to make a few points here and there which could prove worthwhile in the longer term.


Breath Analyzers Market worth $1,539.1 Million by 2019 – New Report by MarketsandMarkets.

Key players in the global breath analyzers market include Drägerwerk AG; CO. KGaA (Germany), (U.S.), Lifeloc Technologies (U.S.), BACtrack, Inc. (U.S.), Quest Products, Inc. (U.S.), Akers Biosciences, Inc. (U.S.), Intoximeter, Inc. (U.S.), AK GlobalTech corporation (U.S.), Alcohol Countermeasure Systems Corporation (Canada), and EnviteC-Wismar GmbH (Germany).

[norbus] 02/1/2015 12:38

mcm looks like the way you will make money here is the arbitrage USA/UK using your physical stock

[rivaldo] 02/1/2015 08:23

Good to see 2015 starting brightly.

With AKR's $10.2M cash pile not too far off the entire £11M m/cap there's still plenty of upside here imho. Hopefully the NASDAQ price will continue to gain momentum, at least back to the $5.50 IPO price, which would equate to around 350p here in the UK.